874 related articles for article (PubMed ID: 31715421)
21. Precious Gene: The Application of RET-Altered Inhibitors.
Gou Q; Gan X; Li L; Gou Q; Zhang T
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557971
[TBL] [Abstract][Full Text] [Related]
22. Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
Huang Q; Schneeberger VE; Luetteke N; Jin C; Afzal R; Budzevich MM; Makanji RJ; Martinez GV; Shen T; Zhao L; Fung KM; Haura EB; Coppola D; Wu J
Mol Cancer Ther; 2016 Oct; 15(10):2521-2529. PubMed ID: 27496134
[TBL] [Abstract][Full Text] [Related]
23. Targeting RET for thyroid cancer therapy.
Lanzi C; Cassinelli G; Nicolini V; Zunino F
Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
[TBL] [Abstract][Full Text] [Related]
24. Novel Human-Derived
Schubert L; Le AT; Estrada-Bernal A; Doak AE; Yoo M; Ferrara SE; Goodspeed A; Kinose F; Rix U; Tan AC; Doebele RC
Mol Pharmacol; 2021 Jun; 99(6):435-447. PubMed ID: 33795352
[TBL] [Abstract][Full Text] [Related]
25. Targeting RET receptor tyrosine kinase activation in cancer.
Phay JE; Shah MH
Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
[TBL] [Abstract][Full Text] [Related]
26. Targeting RET-rearranged non-small-cell lung cancer: future prospects.
Bronte G; Ulivi P; Verlicchi A; Cravero P; Delmonte A; Crinò L
Lung Cancer (Auckl); 2019; 10():27-36. PubMed ID: 30962732
[TBL] [Abstract][Full Text] [Related]
27. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
28. Pralsetinib: First Approval.
Markham A
Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
Drusbosky LM; Rodriguez E; Dawar R; Ikpeazu CV
J Hematol Oncol; 2021 Mar; 14(1):50. PubMed ID: 33771190
[TBL] [Abstract][Full Text] [Related]
30. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
Wang M; Naganna N; Sintim HO
Bioorg Chem; 2019 Sep; 90():103052. PubMed ID: 31226468
[TBL] [Abstract][Full Text] [Related]
31. Progress and challenges in RET-targeted cancer therapy.
Hu X; Khatri U; Shen T; Wu J
Front Med; 2023 Apr; 17(2):207-219. PubMed ID: 37131086
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Sun F; McCoach CE
Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
[TBL] [Abstract][Full Text] [Related]
33. FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with
Bradford D; Larkins E; Mushti SL; Rodriguez L; Skinner AM; Helms WS; Price LSL; Zirkelbach JF; Li Y; Liu J; Charlab R; Turcu FR; Liang D; Ghosh S; Roscoe D; Philip R; Zack-Taylor A; Tang S; Kluetz PG; Beaver JA; Pazdur R; Theoret MR; Singh H
Clin Cancer Res; 2021 Apr; 27(8):2130-2135. PubMed ID: 33239432
[TBL] [Abstract][Full Text] [Related]
34. Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
Zheng H; Chen ZS; Li J
Drugs Today (Barc); 2021 Oct; 57(10):621-629. PubMed ID: 34713870
[TBL] [Abstract][Full Text] [Related]
35. Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer.
Kassir N; McDougall D; Kuruvilla D; Kim S; Kumar S; Rahman A; Ruf T; Cheeti S; Ankrom W
J Clin Pharmacol; 2024 Jun; 64(6):685-696. PubMed ID: 38337106
[TBL] [Abstract][Full Text] [Related]
36. Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.
Song M; Kim SH; Yoon SK
Arch Pharm Res; 2015 Dec; 38(12):2120-3. PubMed ID: 26377589
[TBL] [Abstract][Full Text] [Related]
37. [Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].
Gao Q; Su J; Xiao F; Lin X; Yang J
Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):853-861. PubMed ID: 34743497
[TBL] [Abstract][Full Text] [Related]
38. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Ferrara R; Auger N; Auclin E; Besse B
J Thorac Oncol; 2018 Jan; 13(1):27-45. PubMed ID: 29128428
[TBL] [Abstract][Full Text] [Related]
39. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
40. Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.
Shi M; Wang W; Zhang J; Li B; Lv D; Wang D; Wang S; Cheng D; Ma T
Cancer Sci; 2022 Jan; 113(1):308-318. PubMed ID: 34710947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
